{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:52:04Z","timestamp":1792032724220,"version":"4.4.0"},"reference-count":146,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2005,7,27]],"date-time":"2005-07-27T00:00:00Z","timestamp":1122422400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1007\/s00277-005-1087-4","type":"journal-article","created":{"date-parts":[[2005,7,26]],"date-time":"2005-07-26T20:41:28Z","timestamp":1122410488000},"page":"697-708","source":"Crossref","is-referenced-by-count":23,"title":["Colony-stimulating factors in the management of neutropenia and its complications"],"prefix":"10.1007","volume":"84","author":[{"given":"Michael","family":"Heuser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,7,27]]},"reference":[{"key":"1087_CR1","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/(SICI)1097-0142(19970315)79:6<1150::AID-CNCR13>3.0.CO;2-Z","volume":"79","author":"Z Rahman","year":"1997","unstructured":"Rahman Z, Esparza-Guerra L, Yap HY, Fraschini G, Bodey G, Hortobagyi G (1997) Chemotherapy-induced neutropenia and fever in patients with metastatic breast carcinoma receiving salvage chemotherapy. Cancer 79:1150\u20131157","journal-title":"Cancer"},{"key":"1087_CR2","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood.V78.11.2791.bloodjournal78112791","volume":"78","author":"GD Demetri","year":"1991","unstructured":"Demetri GD, Griffin JD (1991) Granulocyte colony-stimulating factor and its receptor. Blood 78:2791\u20132808","journal-title":"Blood"},{"key":"1087_CR3","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1182\/blood.V72.6.2074.2074","volume":"72","author":"U Duhrsen","year":"1988","unstructured":"Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D (1988) Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 72:2074\u20132081","journal-title":"Blood"},{"key":"1087_CR4","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/0006-291X(87)91430-6","volume":"144","author":"S Kitagawa","year":"1987","unstructured":"Kitagawa S, Yuo A, Souza LM, Saito M, Miura Y, Takaku F (1987) Recombinant human granulocyte colony-stimulating factor enhances superoxide release in human granulocytes stimulated by the chemotactic peptide. Biochem Biophys Res Commun 144:1143\u20131146","journal-title":"Biochem Biophys Res Commun"},{"key":"1087_CR5","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1182\/blood.V84.6.1737.1737","volume":"84","author":"GJ Lieschke","year":"1994","unstructured":"Lieschke GJ, Grail D, Hodgson G et al (1994) Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 84:1737\u20131746","journal-title":"Blood"},{"key":"1087_CR6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF02787205","volume":"15","author":"M Hoglund","year":"1998","unstructured":"Hoglund M (1998) Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)\u2014what is the difference? Med Oncol 15:229\u2013233","journal-title":"Med Oncol"},{"key":"1087_CR7","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1126\/science.8171324","volume":"264","author":"G Dranoff","year":"1994","unstructured":"Dranoff G, Crawford AD, Sadelain M et al (1994) Involvement of granulocyte\u2013macrophage colony-stimulating factor in pulmonary homeostasis. Science 264:713\u2013716","journal-title":"Science"},{"key":"1087_CR8","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1592\/phco.20.19.1432.34861","volume":"20","author":"G Milkovich","year":"2000","unstructured":"Milkovich G, Moleski RJ, Reitan JF et al (2000) Comparative safety of filgrastim versus sargramostim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy 20:1432\u20131440","journal-title":"Pharmacotherapy"},{"key":"1087_CR9","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1600-0609.1992.tb01586.x","volume":"48","author":"D Hovgaard","year":"1992","unstructured":"Hovgaard D, Schifter S, Rabol A, Mortensen BT, Nissen NI (1992) In vivo kinetics of 111indium-labelled autologous granulocytes following i.v. administration of granulocyte\u2013macrophage colony-stimulating factor (GM-CSF). Eur J Haematol 48:202\u2013207","journal-title":"Eur J Haematol"},{"key":"1087_CR10","first-page":"19","volume":"15","author":"RT Dorr","year":"1993","unstructured":"Dorr RT (1993) Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte\u2013macrophage colony-stimulating factor. Clin Ther 15:19\u201329","journal-title":"Clin Ther"},{"key":"1087_CR11","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1200\/JCO.2000.18.20.3558","volume":"18","author":"H Ozer","year":"2000","unstructured":"Ozer H, Armitage JO, Bennett CL et al (2000) 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American society of clinical oncology growth factors expert panel. J Clin Oncol 18:3558\u20133585","journal-title":"J Clin Oncol"},{"key":"1087_CR12","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1182\/blood.V81.10.2496.2496","volume":"81","author":"DC Dale","year":"1993","unstructured":"Dale DC, Bonilla MA, Davis MW et al (1993) A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 81:2496\u20132502","journal-title":"Blood"},{"key":"1087_CR13","first-page":"555","volume":"353","author":"F Falzetti","year":"1999","unstructured":"Falzetti F, Aversa F, Minelli O, Tabilio A (1999) Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 353:555","journal-title":"Lancet"},{"key":"1087_CR14","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/j.1537-2995.2004.00413.x","volume":"44","author":"H Balaguer","year":"2004","unstructured":"Balaguer H, Galmes A, Ventayol G, Bargay J, Besalduch J (2004) Splenic rupture after granulocyte-colony-stimulating factor mobilization in a peripheral blood progenitor cell donor. Transfusion 44:1260\u20131261","journal-title":"Transfusion"},{"key":"1087_CR15","first-page":"107","volume":"57","author":"KK Jain","year":"1996","unstructured":"Jain KK (1996) Sweet\u2019s syndrome associated with granulocyte colony-stimulating factor. Cutis 57:107\u2013110","journal-title":"Cutis"},{"key":"1087_CR16","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/BF02214945","volume":"14","author":"MF McMullin","year":"1995","unstructured":"McMullin MF, Finch MB (1995) Felty\u2019s syndrome treated with rhG-CSF associated with flare of arthritis and skin rash. Clin Rheumatol 14:204\u2013208","journal-title":"Clin Rheumatol"},{"key":"1087_CR17","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/sj.bmt.1701486","volume":"22","author":"JA Snowden","year":"1998","unstructured":"Snowden JA, Biggs JC, Milliken ST et al (1998) A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis. Bone Marrow Transplant 22:1035\u20131041","journal-title":"Bone Marrow Transplant"},{"key":"1087_CR18","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(05)60614-9","volume":"351","author":"M Abboud","year":"1998","unstructured":"Abboud M, Laver J, Blau CA (1998) Granulocytosis causing sickle-cell crisis. Lancet 351:959","journal-title":"Lancet"},{"key":"1087_CR19","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1182\/blood.V97.10.3313","volume":"97","author":"BK Adler","year":"2001","unstructured":"Adler BK, Salzman DE, Carabasi MH, Vaughan WP, Reddy VV, Prchal JT (2001) Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 97:3313\u20133314","journal-title":"Blood"},{"key":"1087_CR20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cyto.2004.09.009","volume":"29","author":"B Rini","year":"2005","unstructured":"Rini B, Wadhwa M, Bird C, Small E, Gaines-Das R, Thorpe R (2005) Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF). Cytokine 29:56\u201366","journal-title":"Cytokine"},{"key":"1087_CR21","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/0140-6736(90)90665-R","volume":"335","author":"JG Gribben","year":"1990","unstructured":"Gribben JG, Devereux S, Thomas NS et al (1990) Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 335:434\u2013437","journal-title":"Lancet"},{"key":"1087_CR22","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood.V100.3.786","volume":"100","author":"S Kojima","year":"2002","unstructured":"Kojima S, Ohara A, Tsuchida M et al (2002) Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood 100:786\u2013790","journal-title":"Blood"},{"key":"1087_CR23","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood.V90.3.1009","volume":"90","author":"A Ohara","year":"1997","unstructured":"Ohara A, Kojima S, Hamajima N et al (1997) Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 90:1009\u20131013","journal-title":"Blood"},{"key":"1087_CR24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1365-2141.1998.01014.x","volume":"103","author":"K Kaito","year":"1998","unstructured":"Kaito K, Kobayashi M, Katayama T et al (1998) Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults. Br J Haematol 103:297\u2013303","journal-title":"Br J Haematol"},{"key":"1087_CR25","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0002-9343(02)01036-7","volume":"112","author":"GH Lyman","year":"2002","unstructured":"Lyman, GH, Kuderer, NM, Djulbegovic, B (2002) Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 112: 406\u2013411","journal-title":"Am J Med"},{"key":"1087_CR26","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2141.2003.04450.x","volume":"122","author":"J Bohlius","year":"2003","unstructured":"Bohlius J, Reiser M, Schwarzer G, Engert A (2003) Impact of granulocyte colony-stimulating factor (CSF) and granulocyte\u2013macrophage CSF in patients with malignant lymphoma: a systematic review. Br J Haematol 122:413\u2013423","journal-title":"Br J Haematol"},{"key":"1087_CR27","first-page":"CD003189","volume":"Rev","author":"Bohlius","year":"2004","unstructured":"Bohlius J, Reiser M, Schwarzer G, Engert A (2004) Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev (3):CD003189","journal-title":"Cochrane Database Syst"},{"key":"1087_CR28","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/jnci\/85.6.488","volume":"85","author":"GH Lyman","year":"1993","unstructured":"Lyman GH, Lyman CG, Sanderson RA, Balducci L (1993) Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 85:488\u2013493","journal-title":"J Natl Cancer Inst"},{"key":"1087_CR29","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0959-8049(98)00222-6","volume":"34","author":"GH Lyman","year":"1998","unstructured":"Lyman GH, Kuderer N, Greene J, Balducci L (1998) The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 34:1857\u20131864","journal-title":"Eur J Cancer"},{"key":"1087_CR30","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1592\/phco.24.5.488.33360","volume":"24","author":"LE Cosler","year":"2004","unstructured":"Cosler LE, Calhoun EA, Agboola O, Lyman GH (2004) Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy 24:488\u2013494","journal-title":"Pharmacotherapy"},{"key":"1087_CR31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3816\/CLM.2001.n.011","volume":"2","author":"VA Morrison","year":"2001","unstructured":"Morrison VA, Picozzi V, Scott S et al (2001) The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin\u2019s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2:47\u201356","journal-title":"Clin Lymphoma"},{"key":"1087_CR32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/107327480200900303","volume":"9","author":"E Chrischilles","year":"2002","unstructured":"Chrischilles E, Delgado DJ, Stolshek BS, Lawless G, Fridman M, Carter WB (2002) Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin\u2019s lymphoma. Cancer Control 9:203\u2013211","journal-title":"Cancer Control"},{"key":"1087_CR33","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/S0959-8049(03)00662-2","volume":"39","author":"L Repetto","year":"2003","unstructured":"Repetto L, Biganzoli L, Koehne CH et al (2003) EORTC cancer in the elderly task force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 39:2264\u20132272","journal-title":"Eur J Cancer"},{"key":"1087_CR34","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1200\/JCO.2005.11.140","volume":"23","author":"A Ardizzoni","year":"2005","unstructured":"Ardizzoni A, Favaretto A, Boni L et al (2005) Platinum\u2013etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis\u2014a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP\u2013GSTPV) study. J Clin Oncol 23:569\u2013575","journal-title":"J Clin Oncol"},{"key":"1087_CR35","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.1998.16.9.3179","volume":"16","author":"KA Phillips","year":"1998","unstructured":"Phillips KA, Tannock IF (1998) Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. J Clin Oncol 16:3179\u20133190","journal-title":"J Clin Oncol"},{"key":"1087_CR36","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.1998.16.2.716","volume":"16","author":"SD Fossa","year":"1998","unstructured":"Fossa SD, Kaye SB, Mead GM et al (1998) Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 16:716\u2013724","journal-title":"J Clin Oncol"},{"key":"1087_CR37","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.1997.15.8.2981","volume":"15","author":"DM Savarese","year":"1997","unstructured":"Savarese DM, Hsieh C, Stewart FM (1997) Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol 15:2981\u20132995","journal-title":"J Clin Oncol"},{"key":"1087_CR38","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(98)01350-6","volume":"352","author":"S Rodenhuis","year":"1998","unstructured":"Rodenhuis S, Richel DJ, van der Wall E et al (1998) Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 352:515\u2013521","journal-title":"Lancet"},{"key":"1087_CR39","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJM200004133421501","volume":"342","author":"EA Stadtmauer","year":"2000","unstructured":"Stadtmauer EA, O\u2019Neill A, Goldstein LJ et al (2000) Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia bone marrow transplant group. N Engl J Med 342:1069\u20131076","journal-title":"N Engl J Med"},{"key":"1087_CR40","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/00001622-200403000-00009","volume":"16","author":"K Chrystal","year":"2004","unstructured":"Chrystal K, Cheong K, Harper P (2004) Chemotherapy of small cell lung cancer: state of the art. Curr Opin Oncol 16:136\u2013140","journal-title":"Curr Opin Oncol"},{"key":"1087_CR41","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Trumper L, Kloess M et al (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634\u2013641","journal-title":"Blood"},{"key":"1087_CR42","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Trumper L, Kloess M et al (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104:626\u2013633","journal-title":"Blood"},{"key":"1087_CR43","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1532\/IJH97.04085","volume":"80","author":"T Kinoshita","year":"2004","unstructured":"Kinoshita T, Hotta T, Tobinai K et al (2004) A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin\u2019s lymphoma: Japan clinical oncology group study 9002. Int J Hematol 80:341\u2013350","journal-title":"Int J Hematol"},{"key":"1087_CR44","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"ML Citron","year":"2003","unstructured":"Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431\u20131439","journal-title":"J Clin Oncol"},{"key":"1087_CR45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00520-001-0312-5","volume":"10","author":"T Berghmans","year":"2002","unstructured":"Berghmans T, Paesmans M, Lafitte JJ et al (2002) Therapeutic use of granulocyte and granulocyte\u2013macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 10:181\u2013188","journal-title":"Support Care Cancer"},{"key":"1087_CR46","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","volume":"18","author":"J Klastersky","year":"2000","unstructured":"Klastersky J, Paesmans M, Rubenstein EB et al (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038\u20133051","journal-title":"J Clin Oncol"},{"key":"1087_CR47","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.1992.10.2.316","volume":"10","author":"JA Talcott","year":"1992","unstructured":"Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10:316\u2013322","journal-title":"J Clin Oncol"},{"key":"1087_CR48","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1056\/NEJM199706193362502","volume":"336","author":"LC Hartmann","year":"1997","unstructured":"Hartmann LC, Tschetter LK, Habermann TM et al (1997) Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 336:1776\u20131780","journal-title":"N Engl J Med"},{"key":"1087_CR49","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","volume":"20","author":"FA Holmes","year":"2002","unstructured":"Holmes FA, O\u2019Shaughnessy JA, Vukelja S et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer. J Clin Oncol 20:727\u2013731","journal-title":"J Clin Oncol"},{"key":"1087_CR50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/mdg019","volume":"14","author":"MD Green","year":"2003","unstructured":"Green MD, Koelbl H, Baselga J et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29\u201335","journal-title":"Ann Oncol"},{"key":"1087_CR51","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel CL, Wojtukiewicz MZ, Carroll RR et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178\u20131184","journal-title":"J Clin Oncol"},{"key":"1087_CR52","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1056\/NEJM199506223322504","volume":"332","author":"H Dombret","year":"1995","unstructured":"Dombret H, Chastang C, Fenaux P et al (1995) A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML cooperative study group. N Engl J Med 332:1678\u20131683","journal-title":"N Engl J Med"},{"key":"1087_CR53","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood.V86.2.457.bloodjournal862457","volume":"86","author":"JM Rowe","year":"1995","unstructured":"Rowe JM, Andersen JW, Mazza JJ et al (1995) A randomized placebo-controlled phase III study of granulocyte\u2013macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the eastern cooperative oncology group (E1490). Blood 86:457\u2013462","journal-title":"Blood"},{"key":"1087_CR54","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJM199506223322503","volume":"332","author":"RM Stone","year":"1995","unstructured":"Stone RM, Berg DT, George SL et al (1995) Granulocyte\u2013macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and leukemia group B. N Engl J Med 332:1671\u20131677","journal-title":"N Engl J Med"},{"key":"1087_CR55","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1200\/JCO.1996.14.7.2150","volume":"14","author":"R Zittoun","year":"1996","unstructured":"Zittoun R, Suciu S, Mandelli F et al (1996) Granulocyte\u2013macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European organization for research and treatment of cancer leukemia cooperative group. J Clin Oncol 14:2150\u20132159","journal-title":"J Clin Oncol"},{"key":"1087_CR56","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1182\/blood.V90.12.4710","volume":"90","author":"G Heil","year":"1997","unstructured":"Heil G, Hoelzer D, Sanz MA et al (1997) A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The international acute myeloid leukemia study group. Blood 90:4710\u20134718","journal-title":"Blood"},{"key":"1087_CR57","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1200\/JCO.1997.15.12.3496","volume":"15","author":"B Lowenberg","year":"1997","unstructured":"Lowenberg B, Boogaerts MA, Daenen SM et al (1997) Value of different modalities of granulocyte\u2013macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 15:3496\u20133506","journal-title":"J Clin Oncol"},{"key":"1087_CR58","first-page":"2952","volume":"90","author":"B Lowenberg","year":"1997","unstructured":"Lowenberg B, Suciu S, Archimbaud E et al (1997) Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the leukemia cooperative group of European organisation for the research and treatment of cancer and the Dutch Belgian hemato-oncology cooperative group. Blood 90:2952\u20132961","journal-title":"Blood"},{"key":"1087_CR59","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1182\/blood.V91.10.3607","volume":"91","author":"JE Godwin","year":"1998","unstructured":"Godwin JE, Kopecky KJ, Head DR et al (1998) A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 91:3607\u20133615","journal-title":"Blood"},{"key":"1087_CR60","first-page":"2722","volume":"91","author":"F Witz","year":"1998","unstructured":"Witz F, Sadoun A, Perrin MC et al (1998) A placebo-controlled study of recombinant human granulocyte\u2013macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. groupe ouest est leucemies aigues myeloblastiques (GOELAM). Blood 91:2722\u20132730","journal-title":"Blood"},{"key":"1087_CR61","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1365-2141.2002.03251.x","volume":"116","author":"K Usuki","year":"2002","unstructured":"Usuki K, Urabe A, Masaoka T et al (2002) Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. Br J Haematol 116:103\u2013112","journal-title":"Br J Haematol"},{"key":"1087_CR62","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1182\/blood.V88.10.3675.bloodjournal88103675","volume":"88","author":"CA Schiffer","year":"1996","unstructured":"Schiffer CA (1996) Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 88:3675\u20133685","journal-title":"Blood"},{"key":"1087_CR63","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO.2000.18.4.780","volume":"18","author":"JL Harousseau","year":"2000","unstructured":"Harousseau JL, Witz B, Lioure B et al (2000) Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the groupe ouest-est leucemies aigues myeloblastiques. J Clin Oncol 18:780\u2013787","journal-title":"J Clin Oncol"},{"key":"1087_CR64","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1046\/j.1365-2141.2003.04546.x","volume":"123","author":"A Pagliuca","year":"2003","unstructured":"Pagliuca A, Carrington PA, Pettengell R, Tule S, Keidan J (2003) Guidelines on the use of colony-stimulating factors in haematological malignancies. Br J Haematol 123:22\u201333","journal-title":"Br J Haematol"},{"key":"1087_CR65","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1182\/blood.V73.5.1272.bloodjournal7351272","volume":"73","author":"J Miyauchi","year":"1989","unstructured":"Miyauchi J, Kelleher CA, Wang C, Minkin S, McCulloch EA (1989) Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood 73:1272\u20131278","journal-title":"Blood"},{"key":"1087_CR66","first-page":"328","volume":"3","author":"SA Cannistra","year":"1989","unstructured":"Cannistra SA, Groshek P, Griffin JD (1989) Granulocyte\u2013macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 3:328\u2013334","journal-title":"Leukemia"},{"key":"1087_CR67","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1182\/blood.V83.8.2086.2086","volume":"83","author":"R Ohno","year":"1994","unstructured":"Ohno R, Naoe T, Kanamaru A et al (1994) A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group. Blood 83:2086\u20132092","journal-title":"Blood"},{"key":"1087_CR68","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1600-0609.1995.tb00689.x","volume":"54","author":"PB Hansen","year":"1995","unstructured":"Hansen PB, Johnsen HE, Jensen L, Gaarsdal E, Simonsen K, Ralfkiaer E (1995) Priming and treatment with molgramostim (rhGM-CSF) in adult high-risk acute myeloid leukemia during induction chemotherapy: a prospective, randomized pilot study. Eur J Haematol 54:296\u2013303","journal-title":"Eur J Haematol"},{"key":"1087_CR69","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1046\/j.1365-2141.1998.00635.x","volume":"100","author":"CA Uyl-de Groot","year":"1998","unstructured":"Uyl-de Groot CA, Lowenberg B, Vellenga E, Suciu S, Willemze R, Rutten FF (1998) Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. Br J Haematol 100:629\u2013636","journal-title":"Br J Haematol"},{"key":"1087_CR70","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/sj.leu.2401474","volume":"13","author":"X Thomas","year":"1999","unstructured":"Thomas X, Fenaux P, Dombret H et al (1999) Granulocyte\u2013macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial). Leukemia 13:1214\u20131220","journal-title":"Leukemia"},{"key":"1087_CR71","first-page":"3","volume":"9","author":"G Heil","year":"1995","unstructured":"Heil G, Chadid L, Hoelzer D et al (1995) GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML). Leukemia 9:3\u20139","journal-title":"Leukemia"},{"key":"1087_CR72","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJMoa025406","volume":"349","author":"B Lowenberg","year":"2003","unstructured":"Lowenberg B, van Putten W, Theobald M et al (2003) Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 349:743\u2013752","journal-title":"N Engl J Med"},{"key":"1087_CR73","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF01696219","volume":"64","author":"R Willemze","year":"1992","unstructured":"Willemze R, van der Lely N, Zwierzina H et al (1992) A randomized phase-I\/II multicenter study of recombinant human granulocyte\u2013macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC leukemia cooperative group. Ann Hematol 64:173\u2013180","journal-title":"Ann Hematol"},{"key":"1087_CR74","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1056\/NEJM198712173172501","volume":"317","author":"S Vadhan-Raj","year":"1987","unstructured":"Vadhan-Raj S, Keating M, LeMaistre A et al (1987) Effects of recombinant human granulocyte\u2013macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317:1545\u20131552","journal-title":"N Engl J Med"},{"key":"1087_CR75","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1182\/blood.V72.2.705.705","volume":"72","author":"JH Antin","year":"1988","unstructured":"Antin JH, Smith BR, Holmes W, Rosenthal DS (1988) Phase I\/II study of recombinant human granulocyte\u2013macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 72:705\u2013713","journal-title":"Blood"},{"key":"1087_CR76","doi-asserted-by":"crossref","first-page":"976","DOI":"10.7326\/0003-4819-110-12-976","volume":"110","author":"RS Negrin","year":"1989","unstructured":"Negrin RS, Haeuber DH, Nagler A et al (1989) Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I\u2013II trial. Ann Intern Med 110:976\u2013984","journal-title":"Ann Intern Med"},{"key":"1087_CR77","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood.V76.1.36.36","volume":"76","author":"RS Negrin","year":"1990","unstructured":"Negrin RS, Haeuber DH, Nagler A et al (1990) Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76:36\u201343","journal-title":"Blood"},{"key":"1087_CR78","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood.V73.1.31.31","volume":"73","author":"A Ganser","year":"1989","unstructured":"Ganser A, Volkers B, Greher J et al (1989) Recombinant human granulocyte\u2013macrophage colony-stimulating factor in patients with myelodysplastic syndromes\u2014a phase I\/II trial. Blood 73:31\u201337","journal-title":"Blood"},{"key":"1087_CR79","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.leu.2401478","volume":"13","author":"GJ Ossenkoppele","year":"1999","unstructured":"Ossenkoppele GJ, van der Holt B, Verhoef GE et al (1999) A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Dutch\u2013Belgian Hemato-Oncology Cooperative Group. Leukemia 13:1207\u20131213","journal-title":"Leukemia"},{"key":"1087_CR80","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1046\/j.1365-2141.1998.00816.x","volume":"102","author":"C Bernasconi","year":"1998","unstructured":"Bernasconi C, Alessandrino EP, Bernasconi P et al (1998) Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS. Br J Haematol 102:678\u2013683","journal-title":"Br J Haematol"},{"key":"1087_CR81","first-page":"196a","volume":"82","author":"P Greenberg","year":"1993","unstructured":"Greenberg P, Taylor K, Larson R et al (1993) Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes (MDS). Proc Am Soc Hematol 82:196a (abstr 768)","journal-title":"Proc Am Soc Hematol"},{"key":"1087_CR82","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood.V82.3.737.737","volume":"82","author":"RS Negrin","year":"1993","unstructured":"Negrin RS, Stein R, Vardiman J et al (1993) Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 82:737\u2013743","journal-title":"Blood"},{"key":"1087_CR83","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1182\/blood.V87.10.4076.bloodjournal87104076","volume":"87","author":"RS Negrin","year":"1996","unstructured":"Negrin, RS, Stein, R, Doherty, K et al (1996) Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 87:4076\u20134081","journal-title":"Blood"},{"key":"1087_CR84","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood.V92.1.68.413k23_68_75","volume":"92","author":"E Hellstrom-Lindberg","year":"1998","unstructured":"Hellstrom-Lindberg E, Ahlgren T, Beguin Y et al (1998) Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92:68\u201375","journal-title":"Blood"},{"key":"1087_CR85","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1182\/blood.V86.2.444.bloodjournal862444","volume":"86","author":"OG Ottmann","year":"1995","unstructured":"Ottmann OG, Hoelzer D, Gracien E et al (1995) Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood 86:444\u2013450","journal-title":"Blood"},{"key":"1087_CR86","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1182\/blood.V87.8.3143.bloodjournal8783143","volume":"87","author":"K Welte","year":"1996","unstructured":"Welte K, Reiter A, Mempel K et al (1996) A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin\u2013Frankfurt\u2013Munster Study Group. Blood 87:3143\u20133150","journal-title":"Blood"},{"key":"1087_CR87","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.V90.2.590","volume":"90","author":"K Geissler","year":"1997","unstructured":"Geissler K, Koller E, Hubmann E et al (1997) Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia\u2014a randomized phase-III study. Blood 90:590\u2013596","journal-title":"Blood"},{"key":"1087_CR88","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJM199706193362503","volume":"336","author":"CH Pui","year":"1997","unstructured":"Pui CH, Boyett JM, Hughes WT et al (1997) Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 336:1781\u20131787","journal-title":"N Engl J Med"},{"key":"1087_CR89","first-page":"1556","volume":"92","author":"RA Larson","year":"1998","unstructured":"Larson RA, Dodge RK, Linker CA et al (1998) A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 92:1556\u20131564","journal-title":"Blood"},{"key":"1087_CR90","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/(SICI)1096-911X(199905)32:5<331::AID-MPO4>3.0.CO;2-M","volume":"32","author":"V Clarke","year":"1999","unstructured":"Clarke V, Dunstan FD, Webb DK (1999) Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia. Med Pediatr Oncol 32:331\u2013335","journal-title":"Med Pediatr Oncol"},{"key":"1087_CR91","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1200\/JCO.2003.07.129","volume":"21","author":"JA Heath","year":"2003","unstructured":"Heath JA, Steinherz PG, Altman A et al (2003) Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a children\u2019s cancer group study. J Clin Oncol 21:1612\u20131617","journal-title":"J Clin Oncol"},{"key":"1087_CR92","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1182\/blood-2002-08-2405","volume":"101","author":"MV Relling","year":"2003","unstructured":"Relling MV, Boyett JM, Blanco JG et al (2003) Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 101:3862\u20133867","journal-title":"Blood"},{"key":"1087_CR93","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/blood.V92.6.1918","volume":"92","author":"A Saven","year":"1998","unstructured":"Saven A, Burian C, Koziol JA, Piro LD (1998) Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 92:1918\u20131926","journal-title":"Blood"},{"key":"1087_CR94","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.V81.8.2031.2031","volume":"81","author":"NJ Chao","year":"1993","unstructured":"Chao NJ, Schriber JR, Grimes K et al (1993) Granulocyte colony-stimulating factor \u201cmobilized\u201d peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 81:2031\u20132035","journal-title":"Blood"},{"key":"1087_CR95","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood.V83.2.610.610","volume":"83","author":"MR Bishop","year":"1994","unstructured":"Bishop MR, Anderson JR, Jackson JD et al (1994) High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte\u2013macrophage colony-stimulating factor on the autograft. Blood 83:610\u2013616","journal-title":"Blood"},{"key":"1087_CR96","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF01696558","volume":"69","author":"T Lamy","year":"1994","unstructured":"Lamy T, Drenou B, Grulois I et al (1994) Improvement of hematologic recovery after high-dose intensification using peripheral blood progenitor cells (PBPC) mobilized by chemotherapy and GM-CSF. Ann Hematol 69:297\u2013302","journal-title":"Ann Hematol"},{"key":"1087_CR97","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1200\/JCO.1994.12.10.2176","volume":"12","author":"A Nademanee","year":"1994","unstructured":"Nademanee A, Sniecinski I, Schmidt GM et al (1994) High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 12:2176\u20132186","journal-title":"J Clin Oncol"},{"key":"1087_CR98","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0140-6736(96)90536-X","volume":"347","author":"N Schmitz","year":"1996","unstructured":"Schmitz N, Linch DC, Dreger P et al (1996) Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347:353\u2013357","journal-title":"Lancet"},{"key":"1087_CR99","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.2000.18.3.537","volume":"18","author":"D Blaise","year":"2000","unstructured":"Blaise D, Kuentz M, Fortanier C et al (2000) Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 18:537\u2013546","journal-title":"J Clin Oncol"},{"key":"1087_CR100","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJM200101183440303","volume":"344","author":"WI Bensinger","year":"2001","unstructured":"Bensinger WI, Martin PJ, Storer B et al (2001) Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344:175\u2013181","journal-title":"N Engl J Med"},{"key":"1087_CR101","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/sj.bmt.1701234","volume":"21","author":"N Schmitz","year":"1998","unstructured":"Schmitz N, Bacigalupo A, Hasenclever D et al (1998) Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21:995\u20131003","journal-title":"Bone Marrow Transplant"},{"key":"1087_CR102","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/sj.bmt.1701422","volume":"22","author":"S Hohaus","year":"1998","unstructured":"Hohaus S, Martin H, Wassmann B et al (1998) Recombinant human granulocyte and granulocyte\u2013macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Bone Marrow Transplant 22:625\u2013630","journal-title":"Bone Marrow Transplant"},{"key":"1087_CR103","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.bbmt.2004.02.001","volume":"10","author":"M Arora","year":"2004","unstructured":"Arora M, Burns LJ, Barker JN et al (2004) Randomized comparison of granulocyte colony-stimulating factor versus granulocyte\u2013macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biol Blood Marrow Transplant 10:395\u2013404","journal-title":"Biol Blood Marrow Transplant"},{"key":"1087_CR104","first-page":"261","volume":"15","author":"N Schmitz","year":"1995","unstructured":"Schmitz N, Dreger P, Zander AR et al (1995) Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 15:261\u2013266","journal-title":"Bone Marrow Transplant"},{"key":"1087_CR105","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.1995.13.6.1323","volume":"13","author":"TR Klumpp","year":"1995","unstructured":"Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, Macdonald JS (1995) Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 13:1323\u20131327","journal-title":"J Clin Oncol"},{"key":"1087_CR106","first-page":"949","volume":"15","author":"J Nemunaitis","year":"1995","unstructured":"Nemunaitis J, Rosenfeld CS, Ash R et al (1995) Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 15:949\u2013954","journal-title":"Bone Marrow Transplant"},{"key":"1087_CR107","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1182\/blood.V92.8.2725","volume":"92","author":"SJ Lee","year":"1998","unstructured":"Lee SJ, Weller E, Alyea EP, Ritz J, Soiffer RJ (1998) Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation. Blood 92:2725\u20132729","journal-title":"Blood"},{"key":"1087_CR108","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/sj.bmt.1701100","volume":"21","author":"BJ Bolwell","year":"1998","unstructured":"Bolwell BJ, Pohlman B, Andresen S et al (1998) Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial. Bone Marrow Transplant 21:369\u2013373","journal-title":"Bone Marrow Transplant"},{"key":"1087_CR109","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/sj.bmt.1701872","volume":"24","author":"IF Ciernik","year":"1999","unstructured":"Ciernik IF, Schanz U, Gmur J (1999) Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial. Bone Marrow Transplant 24:147\u2013151","journal-title":"Bone Marrow Transplant"},{"key":"1087_CR110","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/sj.bmt.1701469","volume":"22","author":"I Bence-Bruckler","year":"1998","unstructured":"Bence-Bruckler I, Bredeson C, Atkins H et al (1998) A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant 22:965\u2013969","journal-title":"Bone Marrow Transplant"},{"key":"1087_CR111","first-page":"Abstr","volume":"22","author":"Schleuning","year":"2005","unstructured":"Schleuning M, Thoedtmann R, Josten K, Baurmann H, Schwerdtfeger R (2005) The impact of post transplant use of G-CSF on event free survival in AML patients undergoing allogeneic stem cell transplantation from unrelated donors and in vivo T-cell depletion with ATG. J Clin Oncol 2004 ASCO Annu Meet Proc 22:Abstr 6637","journal-title":"J Clin Oncol 2004 ASCO Annu Meet Proc"},{"key":"1087_CR112","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/00062752-199805000-00014","volume":"5","author":"M Kumar","year":"1998","unstructured":"Kumar M, Alter BP (1998) Hematopoietic growth factors for the treatment of aplastic anemia. Curr Opin Hematol 5:226\u2013234","journal-title":"Curr Opin Hematol"},{"key":"1087_CR113","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1046\/j.1365-2141.2002.03947.x","volume":"119","author":"E Gluckman","year":"2002","unstructured":"Gluckman E, Rokicka-Milewska R, Hann I et al (2002) Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol 119:1075\u20131082","journal-title":"Br J Haematol"},{"key":"1087_CR114","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1600-0609.1997.tb01665.x","volume":"58","author":"M Bessho","year":"1997","unstructured":"Bessho M, Hirashima K, Asano S et al (1997) Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled study. Multicenter Study Group. Eur J Haematol 58:265\u2013272","journal-title":"Eur J Haematol"},{"key":"1087_CR115","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1182\/blood.V88.5.1588.1588","volume":"88","author":"WR Rackoff","year":"1996","unstructured":"Rackoff WR, Orazi A, Robinson CA et al (1996) Prolonged administration of granulocyte colony-stimulating factor (filgrastim) to patients with Fanconi anemia: a pilot study. Blood 88:1588\u20131593","journal-title":"Blood"},{"key":"1087_CR116","first-page":"432","volume":"83","author":"P Scagni","year":"1998","unstructured":"Scagni P, Saracco P, Timeus F et al (1998) Use of recombinant granulocyte colony-stimulating factor in Fanconi\u2019s anemia. Haematologica 83:432\u2013437","journal-title":"Haematologica"},{"key":"1087_CR117","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1056\/NEJM198906153202402","volume":"320","author":"MA Bonilla","year":"1989","unstructured":"Bonilla MA, Gillio AP, Ruggeiro M et al (1989) Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med 320:1574\u20131580","journal-title":"N Engl J Med"},{"key":"1087_CR118","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood.V75.5.1056.1056","volume":"75","author":"K Welte","year":"1990","unstructured":"Welte K, Zeidler C, Reiter A et al (1990) Differential effects of granulocyte\u2013macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia. Blood 75:1056\u20131063","journal-title":"Blood"},{"key":"1087_CR119","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/0090-1229(92)90039-Q","volume":"62","author":"LA Boxer","year":"1992","unstructured":"Boxer LA, Hutchinson R, Emerson S (1992) Recombinant human granulocyte-colony-stimulating factor in the treatment of patients with neutropenia. Clin Immunol Immunopathol 62:S39\u2013S46","journal-title":"Clin Immunol Immunopathol"},{"key":"1087_CR120","doi-asserted-by":"crossref","first-page":"887","DOI":"10.7326\/0003-4819-111-11-887","volume":"111","author":"A Ganser","year":"1989","unstructured":"Ganser A, Ottmann OG, Erdmann H, Schulz G, Hoelzer D (1989) The effect of recombinant human granulocyte\u2013macrophage colony-stimulating factor on neutropenia and related morbidity in chronic severe neutropenia. Ann Intern Med 111:887\u2013892","journal-title":"Ann Intern Med"},{"key":"1087_CR121","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.10255","volume":"72","author":"DC Dale","year":"2003","unstructured":"Dale DC, Cottle TE, Fier CJ et al (2003) Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 72:82\u201393","journal-title":"Am J Hematol"},{"key":"1087_CR122","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1182\/blood.V70.5.1343.1343","volume":"70","author":"AG Leary","year":"1987","unstructured":"Leary AG, Yang YC, Clark SC, Gasson JC, Golde DW, Ogawa M (1987) Recombinant gibbon interleukin 3 supports formation of human multilineage colonies and blast cell colonies in culture: comparison with recombinant human granulocyte\u2013macrophage colony-stimulating factor. Blood 70:1343\u20131348","journal-title":"Blood"},{"key":"1087_CR123","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/blood.V76.3.455.455","volume":"76","author":"A Ganser","year":"1990","unstructured":"Ganser A, Seipelt G, Lindemann A et al (1990) Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 76:455\u2013462","journal-title":"Blood"},{"key":"1087_CR124","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood.V76.4.666.666","volume":"76","author":"A Ganser","year":"1990","unstructured":"Ganser A, Lindemann A, Seipelt G et al (1990) Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 76:666\u2013676","journal-title":"Blood"},{"key":"1087_CR125","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1182\/blood.V82.11.3273.3273","volume":"82","author":"J Nemunaitis","year":"1993","unstructured":"Nemunaitis J, Appelbaum FR, Singer JW et al (1993) Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation. Blood 82:3273\u20133278","journal-title":"Blood"},{"key":"1087_CR126","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1200\/JCO.1991.9.12.2120","volume":"9","author":"A Lindemann","year":"1991","unstructured":"Lindemann A, Ganser A, Herrmann F et al (1991) Biologic effects of recombinant human interleukin-3 in vivo. J Clin Oncol 9:2120\u20132127","journal-title":"J Clin Oncol"},{"key":"1087_CR127","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.1998.16.10.3335","volume":"16","author":"LS Hofstra","year":"1998","unstructured":"Hofstra LS, Kristensen GB, Willemse PH et al (1998) Randomized trial of recombinant human interleukin-3 versus placebo in prevention of bone marrow depression during first-line chemotherapy for ovarian carcinoma. J Clin Oncol 16:3335\u20133344","journal-title":"J Clin Oncol"},{"key":"1087_CR128","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1182\/blood.V79.10.2583.2583","volume":"79","author":"A Ganser","year":"1992","unstructured":"Ganser A, Lindemann A, Ottmann OG et al (1992) Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte\u2013macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: results of a phase I study. Blood 79:2583\u20132591","journal-title":"Blood"},{"key":"1087_CR129","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3816\/CBC.2002.n.030","volume":"3","author":"JM Nabholtz","year":"2002","unstructured":"Nabholtz JM, Cantin J, Chang J et al (2002) Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel\/doxorubicin\/cyclophosphamide: results of the BCIRG 004 trial. Clin Breast Cancer 3:268\u2013275","journal-title":"Clin Breast Cancer"},{"key":"1087_CR130","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1634\/stemcells.19-4-329","volume":"19","author":"AM Farese","year":"2001","unstructured":"Farese AM, Smith WG, Giri JG, Siegel N, McKearn JP, MacVittie TJ (2001) Promegapoietin-1a, an engineered chimeric IL-3 and Mpl-L receptor agonist, stimulates hematopoietic recovery in conventional and abbreviated schedules following radiation-induced myelosuppression in nonhuman primates. Stem Cells 19:329\u2013338","journal-title":"Stem Cells"},{"key":"1087_CR131","first-page":"1121","volume":"23","author":"HE Broxmeyer","year":"1995","unstructured":"Broxmeyer HE, Lu L, Cooper S, Ruggieri L, Li ZH, Lyman SD (1995) Flt3 ligand stimulates\/costimulates the growth of myeloid stem\/progenitor cells. Exp Hematol 23:1121\u20131129","journal-title":"Exp Hematol"},{"key":"1087_CR132","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1084\/jem.192.5.719","volume":"192","author":"S Zhang","year":"2000","unstructured":"Zhang S, Fukuda S, Lee Y et al (2000) Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med 192:719\u2013728","journal-title":"J Exp Med"},{"key":"1087_CR133","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1182\/blood.V89.11.3998","volume":"89","author":"G Molineux","year":"1997","unstructured":"Molineux G, McCrea C, Yan XQ, Kerzic P, McNiece I (1997) Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential. Blood 89:3998\u20134004","journal-title":"Blood"},{"key":"1087_CR134","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0301-472X(01)00675-0","volume":"29","author":"WH Fleming","year":"2001","unstructured":"Fleming WH, Mulcahy JM, McKearn JP, Streeter PR (2001) Progenipoietin-1: a multifunctional agonist of the granulocyte colony-stimulating factor receptor and fetal liver tyrosine kinase-3 is a potent mobilizer of hematopoietic stem cells. Exp Hematol 29:943\u2013951","journal-title":"Exp Hematol"},{"key":"1087_CR135","first-page":"5228","volume":"9","author":"RS Freedman","year":"2003","unstructured":"Freedman RS, Vadhan-Raj S, Butts C et al (2003) Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas. Clin Cancer Res 9:5228\u20135237","journal-title":"Clin Cancer Res"},{"key":"1087_CR136","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.2003.04.040","volume":"21","author":"JM Nabholtz","year":"2003","unstructured":"Nabholtz JM, Falkson C, Campos D et al (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21:968\u2013975","journal-title":"J Clin Oncol"},{"key":"1087_CR137","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1200\/JCO.2002.11.005","volume":"20","author":"L Biganzoli","year":"2002","unstructured":"Biganzoli L, Cufer T, Bruning P et al (2002) Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European organization for research and treatment of cancer 10961 multicenter phase III trial. J Clin Oncol 20:3114\u20133121","journal-title":"J Clin Oncol"},{"key":"1087_CR138","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00130404-200307000-00007","volume":"9","author":"AA Meluch","year":"2003","unstructured":"Meluch AA, Greco FA, Gray JR et al (2003) Preoperative therapy with concurrent paclitaxel\/carboplatin\/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a minnie pearl cancer research network phase II trial. Cancer J 9:251\u2013260","journal-title":"Cancer J"},{"key":"1087_CR139","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","volume":"19","author":"CN Sternberg","year":"2001","unstructured":"Sternberg CN, De Mulder PH, Schornagel JH et al (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European organization for research and treatment of cancer protocol no. 30924. J Clin Oncol 19:2638\u20132646","journal-title":"J Clin Oncol"},{"key":"1087_CR140","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1200\/JCO.1998.16.1.255","volume":"16","author":"DJ Vaughn","year":"1998","unstructured":"Vaughn DJ, Malkowicz SB, Zoltick B et al (1998) Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol 16:255\u2013260","journal-title":"J Clin Oncol"},{"key":"1087_CR141","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1200\/JCO.1999.17.9.2676","volume":"17","author":"PG Rose","year":"1999","unstructured":"Rose PG, Blessing JA, Gershenson DM, McGehee R (1999) Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 17:2676\u20132680","journal-title":"J Clin Oncol"},{"key":"1087_CR142","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1200\/JCO.1998.16.4.1325","volume":"16","author":"DM Shin","year":"1998","unstructured":"Shin DM, Glisson BS, Khuri FR et al (1998) Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 16:1325\u20131330","journal-title":"J Clin Oncol"},{"key":"1087_CR143","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","volume":"17","author":"J Pawel von","year":"1999","unstructured":"von Pawel J, Schiller JH, Shepherd FA et al (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658\u2013667","journal-title":"J Clin Oncol"},{"key":"1087_CR144","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","volume":"71","author":"WS Velasquez","year":"1988","unstructured":"Velasquez WS, Cabanillas F, Salvador P et al (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71:117\u2013122","journal-title":"Blood"},{"key":"1087_CR145","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","volume":"12","author":"WS Velasquez","year":"1994","unstructured":"Velasquez WS, McLaughlin P, Tucker S et al (1994) ESHAP\u2014an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 12:1169\u20131176","journal-title":"J Clin Oncol"},{"key":"1087_CR146","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","volume":"103","author":"T Kewalramani","year":"2004","unstructured":"Kewalramani T, Zelenetz AD, Nimer SD et al (2004) Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103:3684\u20133688","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-005-1087-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-005-1087-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-005-1087-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T10:48:10Z","timestamp":1586342890000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-005-1087-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,27]]},"references-count":146,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["1087"],"URL":"https:\/\/doi.org\/10.1007\/s00277-005-1087-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,27]]}}}